Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer

IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Won-Gun Yun, Tae Young Kim, Seulah Park, Youngmin Han, Go-Won Choi, Hye-Sol Jung, Wooil Kwon, Joon Seong Park, Gi Jeong Cheon, Jin-Young Jang
{"title":"Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer","authors":"Won-Gun Yun,&nbsp;Tae Young Kim,&nbsp;Seulah Park,&nbsp;Youngmin Han,&nbsp;Go-Won Choi,&nbsp;Hye-Sol Jung,&nbsp;Wooil Kwon,&nbsp;Joon Seong Park,&nbsp;Gi Jeong Cheon,&nbsp;Jin-Young Jang","doi":"10.1002/jhbp.12122","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>With the evolving treatment paradigms for pancreatic cancer, there is an increasing need for reliable markers to evaluate the effectiveness of preoperative chemotherapy. Due to the limitations of current indicators, this study aimed to evaluate the prognostic value of metabolic response based on the changes in the maximum standardized uptake value (SUV<sub>max</sub>) on fluorine-18-fluorodeoxyglucose positron emission tomography.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study included 210 patients with pancreatic cancer who underwent post-chemotherapy curative surgery between 2013 and 2022. Using maximally selected rank statistics for survival, the metabolic response was defined as follows: metabolic responder (%ΔSUV<sub>max</sub> &gt;75%), metabolic stable disease (15%–75%), and metabolic non-responder (≤15%).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among patients, 15.7%, 66.7%, and 11.6% were categorized into the metabolic responder, metabolic stable disease, and metabolic non-responder groups. The metabolic responder group (83.0 months) had longer median overall survival than the metabolic stable disease (51.0 months, <i>p</i> = .013) and metabolic non-responder (32.0 months, <i>p</i> = .002) groups. In addition, being metabolic responders (vs. non-responders) was an independent predictor of low recurrence rates (hazard ratio [95% confidence interval]: 0.46 [0.23–0.91]; <i>p</i> = .026) and achieving pathologic complete response (odds ratio [95% confidence interval]: 13.39 [1.61–300.77]; <i>p</i> = .035).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Metabolic response during preoperative chemotherapy has predictive power for post-resection prognosis and residual tumor status.</p>\n </section>\n </div>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":"32 5","pages":"393-403"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jhbp.12122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

With the evolving treatment paradigms for pancreatic cancer, there is an increasing need for reliable markers to evaluate the effectiveness of preoperative chemotherapy. Due to the limitations of current indicators, this study aimed to evaluate the prognostic value of metabolic response based on the changes in the maximum standardized uptake value (SUVmax) on fluorine-18-fluorodeoxyglucose positron emission tomography.

Methods

This study included 210 patients with pancreatic cancer who underwent post-chemotherapy curative surgery between 2013 and 2022. Using maximally selected rank statistics for survival, the metabolic response was defined as follows: metabolic responder (%ΔSUVmax >75%), metabolic stable disease (15%–75%), and metabolic non-responder (≤15%).

Results

Among patients, 15.7%, 66.7%, and 11.6% were categorized into the metabolic responder, metabolic stable disease, and metabolic non-responder groups. The metabolic responder group (83.0 months) had longer median overall survival than the metabolic stable disease (51.0 months, p = .013) and metabolic non-responder (32.0 months, p = .002) groups. In addition, being metabolic responders (vs. non-responders) was an independent predictor of low recurrence rates (hazard ratio [95% confidence interval]: 0.46 [0.23–0.91]; p = .026) and achieving pathologic complete response (odds ratio [95% confidence interval]: 13.39 [1.61–300.77]; p = .035).

Conclusions

Metabolic response during preoperative chemotherapy has predictive power for post-resection prognosis and residual tumor status.

胰腺癌术前化疗期间的代谢反应可预测预后。
背景:随着胰腺癌治疗模式的不断发展,越来越需要可靠的标志物来评估术前化疗的有效性。由于现有指标的局限性,本研究旨在通过氟-18-氟脱氧葡萄糖正电子发射断层扫描最大标准化摄取值(SUVmax)的变化来评价代谢反应的预后价值。方法:本研究纳入2013年至2022年间接受化疗后治愈性手术的210例胰腺癌患者。采用最大选择的生存秩统计,将代谢应答定义为:代谢应答(%ΔSUVmax >75%)、代谢稳定疾病(15%-75%)和代谢无应答(≤15%)。结果:15.7%、66.7%和11.6%的患者分为代谢缓解组、代谢稳定组和代谢无缓解组。代谢缓解组(83.0个月)的中位总生存期长于代谢稳定疾病组(51.0个月,p = 0.013)和代谢无缓解组(32.0个月,p = 0.002)。此外,代谢应答者(相对于无应答者)是低复发率的独立预测因子(风险比[95%置信区间]:0.46 [0.23-0.91];P = 0.026),达到病理完全缓解(优势比[95%可信区间]:13.39 [1.61-300.77];p = .035)。结论:术前化疗期间代谢反应对术后预后和肿瘤残留状态具有预测作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Hepato‐Biliary‐Pancreatic Sciences
Journal of Hepato‐Biliary‐Pancreatic Sciences GASTROENTEROLOGY & HEPATOLOGY-SURGERY
自引率
10.00%
发文量
178
审稿时长
6-12 weeks
期刊介绍: The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信